BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis


3/17/2009 9:29:57 AM

EXTON, Pa., March 16 /PRNewswire/ -- BioTrends Research Group, Inc. has been covering the biologics market for Psoriasis and RA through its TreatmentTrends(TM) series which are syndicated primary research reports based on self reported survey data collected from Dermatologists and Rheumatologists. The company is now expanding these offerings in the form of ChartTrends(TM) reports which aim to compare self-reported treatment patterns with actual patient level data.

The ChartTrends(TM) reports will each offer comprehensive insight into the management and use of biologics used in the treatment of Rheumatoid Arthritis (RA) and Psoriasis. Each report is derived from analysis of actual patient chart data and laboratory results collected from over 1,000 RA and Psoriasis patients currently being treated with biologics. The retrospective audit captures a wide range of patient demographic data, the range of dose variability, co-morbidities, concomitant medications, and laboratory values for the past year. Medication changes and actions taken during office visits are highlighted to understand the triggers for therapy initiation and adjustment. The final report also compares the self-reported practice patterns with actual patient records in order identify gaps in care.

These studies are being undertaken to understand the treatment algorithm for biologic initiation, how each of the biologic brands is typically used, what triggers brand switching, and what patient characteristics (age, co-morbidities, insurance type) influence treatment decisions. Additionally, the study will assess familiarity and interest in several late stage biologics in development (Roche's ACTEMRA, Centocor's SIMPONI, and UCB's CIMZIA in RA and Centocor's STELARA and Abbott's ABT-874 in Psoriasis). BioTrends, which has been offering ChartTrends(TM) reports since 2005, plans to publish the findings in June.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

CONTACT: Jennifer Robinson of BioTrends Research Group, Inc.,
+1-610-363-3872

Web site: http://www.bio-trends.com/



Read at BioSpace.com

BioTrends
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES